An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain

5Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Influenza infections impose a high burden of morbidity and mortality among older adults, at great cost to individuals and society. Enhanced influenza vaccines, which contain either an immune adjuvant or higher than normal doses of influenza virus antigens, are recommended for older adults. We used a health economics model to evaluate the cost effectiveness in Spain of a recently licensed recombinant quadrivalent influenza vaccine (QIVr), which contains three times the standard dose of influenza virus hemagglutinin but no neuraminidase, compared with an MF59-adjuvanted quadrivalent influenza vaccine (aQIV). Based on current tender prices in Spain and a conservative assumption that QIVr is 10.7% relatively more effective than aQIV, the incremental cost-effectiveness ratio (ICER) for QIVr was EUR 101,612.41 per quality-adjusted life year (QALY) gained. To meet the Spanish willingness-to-pay threshold of EUR 25,000 per QALY gained, QIVr would need to be 34.1% relatively more effective than aQIV. In a probabilistic sensitivity analysis conducted to confirm the robustness of the analysis, 99.7% of simulations for QIVr were higher than the willingness-to-pay curve. These findings suggest that QIVr is not currently a cost-effective influenza vaccine option relative to aQIV for older persons living in Spain.

References Powered by Scopus

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

2061Citations
N/AReaders
Get full text

Efficacy of high-dose versus standard-dose influenza vaccine in older adults

659Citations
N/AReaders
Get full text

Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project

449Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

10Citations
N/AReaders
Get full text

Use of Adjuvanted Quadrivalent Influenza Vaccine in Older-Age Adults: A Systematic Review of Economic Evidence

2Citations
N/AReaders
Get full text

Critical assessment of uncertainty in economic evaluations on influenza vaccines for the elderly population in Spain

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ruiz-Aragón, J., & Márquez-Peláez, S. (2023). An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain. Vaccines, 11(2). https://doi.org/10.3390/vaccines11020427

Readers' Seniority

Tooltip

Researcher 1

100%

Readers' Discipline

Tooltip

Decision Sciences 1

33%

Medicine and Dentistry 1

33%

Nursing and Health Professions 1

33%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free